Show simple item record

dc.contributor.authorPliarchopoulou, K.en
dc.contributor.authorKalogeras, K. T.en
dc.contributor.authorKronenwett, R.en
dc.contributor.authorWirtz, R. M.en
dc.contributor.authorEleftheraki, A. G.en
dc.contributor.authorBatistatou, Annaen
dc.contributor.authorBobos, M.en
dc.contributor.authorSoupos, N.en
dc.contributor.authorPolychronidou, G.en
dc.contributor.authorGogas, H.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorFountzilas, Georgeen
dc.creatorPliarchopoulou, K.en
dc.creatorKalogeras, K. T.en
dc.creatorKronenwett, R.en
dc.creatorWirtz, R. M.en
dc.creatorEleftheraki, A. G.en
dc.creatorBatistatou, Annaen
dc.creatorBobos, M.en
dc.creatorSoupos, N.en
dc.creatorPolychronidou, G.en
dc.creatorGogas, H.en
dc.creatorSamantas, E.en
dc.creatorChristodoulou, C.en
dc.creatorMakatsoris, T.en
dc.creatorPavlidis, Nicholasen
dc.creatorPectasides, Dimitriosen
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:52:46Z
dc.date.available2018-06-22T09:52:46Z
dc.date.issued2013
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41495
dc.description.abstractPurpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 mRNA expression on disease-free survival (DFS) and overall survival (OS) in high-risk early breast cancer patients and compare it to that of Ki67 protein expression and to the Nottingham prognostic index (NPI). Methods: A total of 595 high-risk breast cancer patients were treated in a two-arm trial evaluating postoperative dose-dense sequential chemotherapy with epirubicin followed by CMF with or without paclitaxel. RNA was extracted from 314 formalin-fixed paraffin-embedded primary tumor tissue samples followed by one-step quantitative RT-PCR for assessing RACGAP1 mRNA expression. Results: High RACGAP1 mRNA expression (above the median) was associated with poor DFS (log-rank, p = 0.002) and OS (p < 0.001). High histological grade, as well as high Ki67 protein expression, was more frequent in the high-expression group of RACGAP1. Results of the Cox multivariate regression analysis revealed that high RACGAP1 mRNA expression independently predicted poor overall survival (Wald's p = 0.008). High Ki67 protein expression was also an adverse prognostic factor for death (p = 0.016), while high NPI score values were not. Conclusions: High RACGAP1 mRNA expression, as assessed by qRT-PCR, was found to be of adverse prognostic significance in high-risk early breast cancer patients treated with dose-dense sequential chemotherapy. The utility of RACGAP1 mRNA expression in patient selection for treatment with aggressive chemotherapy regimens should be further explored and validated in larger cohorts. © 2012 Springer-Verlag Berlin Heidelberg.en
dc.language.isoengen
dc.sourceCancer chemotherapy and pharmacologyen
dc.subjectArticleen
dc.subjectFemaleen
dc.subjectYoung adulten
dc.subjectCyclophosphamideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectRegression analysisen
dc.subjectCancer survivalen
dc.subjectPaclitaxelen
dc.subjectPredictionen
dc.subjectPriority journalen
dc.subjectQuantitative analysisen
dc.subjectRetrospective studiesen
dc.subjectRetrospective studyen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectDisease-free survivalen
dc.subjectDrug effecten
dc.subjectHuman tissueen
dc.subjectPrognosisen
dc.subjectDisease free survivalen
dc.subjectNeoplasticen
dc.subjectOverall survivalen
dc.subjectCancer prognosisen
dc.subjectSurvival rateen
dc.subjectEpirubicinen
dc.subjectRisk assessmenten
dc.subjectProtein expressionen
dc.subjectCancer risken
dc.subjectGene expression regulationen
dc.subjectHigh risk patienten
dc.subjectProtein determinationen
dc.subjectUnclassified drugen
dc.subjectBreast canceren
dc.subjectCancer gradingen
dc.subjectHistopathologyen
dc.subjectOncogeneen
dc.subjectSurvival timeen
dc.subjectRandomized controlled trial (topic)en
dc.subjectRandomized controlled trials as topicen
dc.subjectRisk factoren
dc.subjectDisease associationen
dc.subjectPatient selectionen
dc.subjectGene expressionen
dc.subjectRnaen
dc.subjectMultivariate analysisen
dc.subjectMessenger rnaen
dc.subjectReverse transcription polymerase chain reactionen
dc.subjectKi 67 antigenen
dc.subjectEarly canceren
dc.subjectScoring systemen
dc.subjectProportional hazards modelsen
dc.subjectPrognostic valueen
dc.subjectGene functionen
dc.subjectMessengeren
dc.subjectReverse transcriptase polymerase chain reactionen
dc.subjectGene identificationen
dc.subjectGtpase-activating proteinsen
dc.subjectGuanosine triphosphatase activating proteinen
dc.subjectKi-67 antigenen
dc.subjectKi67en
dc.subjectNottingham prognostic indexen
dc.subjectQrt-pcren
dc.subjectRac gtpase activating protein 1en
dc.subjectRac gtpase activating protein 1 geneen
dc.subjectRacgap1en
dc.titlePrognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trialen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00280-012-2002-z
dc.description.volume71
dc.description.issue1
dc.description.startingpage245
dc.description.endingpage255
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record